Frecuencia, factores predictores y consecuencias de la intensificación del tratamiento de mantenimiento con infliximab en la colitis ulcerosa

  1. Luis Ignacio Fernández Salazar
  2. Jesús Barrio Andrés
  3. Fernando Muñoz
  4. Concepción Muñoz
  5. Ramón Pajares Villarroya
  6. M. Rivero
  7. Vanesa Prieto Vicente
  8. Jesús Legido
  9. Abdel Bouhmidi
  10. Maite Herranz
  11. Guillermo González Redondo
  12. Nereida Fernández Fernández
  13. Fernando Santos
  14. Ramón Sánchez-Ocaña
  15. Diana Joao Matías
  16. Investigadores de ACAD
Journal:
Revista Española de Enfermedades Digestivas

ISSN: 2340-416 1130-0108

Year of publication: 2015

Volume: 107

Issue: 9

Pages: 527-533

Type: Article

DOI: 10.17235/REED.2015.3804/2015 DIALNET GOOGLE SCHOLAR

More publications in: Revista Española de Enfermedades Digestivas

Sustainable development goals

Abstract

Introduction: Infliximab (IFX) therapy intensification in ulcerative colitis (UC) is more common than established in pivotal studies. Objectives: To establish the frequency and form of intensification for UC in clinical practice, as well as predictors, and to compare outcomes between intensified and non-intensified treatment. Methods: A retrospective study of 10 hospitals and 144 patients with response to infliximab (IFX) induction. Predictive variables for intensification were analyzed using a Cox regression analysis. Outcome, loss of response to IFX, and colectomy were compared between intensified and non-intensified therapy. Results: Follow-up time from induction to data collection: 38 months [interquartile range (IQR), 20-62]. Time on IFX therapy: 24 months (IQR, 10-44). In all, 37% of patients required intensification. Interval was shortened for 36 patients, dose was increased for 7, and 10 subjects received both. Concurrent thiopurine immunosuppressants (IMM) and IFX initiation was an independent predictor of intensification [Hazard ratio, 0.034; p, 0.006; CI, 0.003-0.371]. In patients on intensified therapy IFX discontinuation for loss of response (30.4% vs. 10.2%; p, 0.002), steroid reintroduction (35% vs. 18%; p, 0.018), and colectomy (22% vs. 6.4%; p, 0.011) were more common. Of patients on intensification, 17% returned to receiving 5 mg/kg every 8 weeks. Conclusions: Intensification is common and occasionally reversible. IMM initiation at the time of induction with IFX predicts non-intensification. Intensification, while effective, is associated with poorer outcome.